USA Tnma

Peak Bio, Inc., based in Pleasanton, CA, is a biopharmaceutical company focused on developing innovative therapies for inflammatory rare and specialty diseases, as well as cancer. With a management team boasting over 50 years of industry experience, the company is dedicated to addressing significant unmet medical needs through its research and development in antibody-drug conjugates and small molecule therapeutics. One of their notable investigational therapies is PHP-303, a small molecule inhibitor of Neutrophil Elastase aimed at treating a rare genetic condition known as Alpha-1 Antitrypsin Deficiency (AATD). Additionally, Peak Bio is exploring novel toxins and antibody-drug conjugates (ADCs) that combine the precision of monoclonal antibodies with the potent effects of targeted small molecule therapies for oncology applications. Generated from the website

Astex Pharmaceuticals, a member of the Otsuka Group, is dedicated to advancing oncology through innovative research and development. The company focuses on discovering and developing targeted therapeutics for cancer treatment, with a robust clinical pipeline that includes various inhibitors and antagonists aimed at specific oncogenic pathways. Committed to corporate social responsibility, Astex emphasizes sustainability and collaboration within the healthcare community. Their proprietary products and programs, such as Tolinapant and ASTX660, aim to address unmet medical needs in oncology and beyond. Generated from the website

Celagenex LLC is a research and development company based in San Ramon, CA, dedicated to addressing the growing global burden of chronic lifestyle diseases. With a focus on unhealthy diet and nutrition, among other factors, Celagenex aims to contribute to the reduction of chronic diseases and improve overall global health. As the proportion of global deaths due to chronic lifestyle diseases is projected to increase to 70% by 2030, Celagenex is committed to advancing research and development in this field to combat the rising global burden of disease.Generated from the website